{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T23:45:21Z","timestamp":1768434321319,"version":"3.49.0"},"reference-count":74,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ejso.2025.111187","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T10:06:36Z","timestamp":1763373996000},"page":"111187","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Theranostics in surgical oncology"],"prefix":"10.1016","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5226-7597","authenticated-orcid":false,"given":"S.","family":"St\u00e4ttner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7594-4354","authenticated-orcid":false,"given":"Kjetil","family":"Soreide","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Hallet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara Maria","family":"Grana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8938-6170","authenticated-orcid":false,"given":"Stefan","family":"Partelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9662-7259","authenticated-orcid":false,"given":"Ken","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1990-2584","authenticated-orcid":false,"given":"Andreas","family":"Brandl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejso.2025.111187_bib1","doi-asserted-by":"crossref","first-page":"13S","DOI":"10.2967\/jnumed.118.220566","article-title":"Future of theranostics: an outlook on precision oncology in nuclear medicine","volume":"60","author":"Langbein","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ejso.2025.111187_bib2","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.2147\/OTT.S140671","article-title":"Theranostics in nuclear medicine practice","volume":"10","author":"Yordanova","year":"2017","journal-title":"OncoTargets Ther"},{"key":"10.1016\/j.ejso.2025.111187_bib3","doi-asserted-by":"crossref","first-page":"263S","DOI":"10.2967\/jnumed.120.254532","article-title":"The future of nuclear medicine, molecular imaging, and theranostics","volume":"61","author":"Weber","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ejso.2025.111187_bib4","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1001\/jama.1946.02870190005002","article-title":"Radioactive iodine in the study of thyroid physiology: VII. The use of radioactive iodine therapy in hyperthyroidism","volume":"131","author":"Hertz","year":"1946","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.ejso.2025.111187_bib5","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41573-020-0073-9","article-title":"Radiopharmaceutical therapy in cancer: clinical advances and challenges","volume":"19","author":"Sgouros","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ejso.2025.111187_bib6","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S0140-6736(89)91258-0","article-title":"Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin","volume":"333","author":"Krenning","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.ejso.2025.111187_bib7","series-title":"Indium In-111 pentetreotide kit","year":"1994"},{"key":"10.1016\/j.ejso.2025.111187_bib8","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1023\/A:1011160913619","article-title":"The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study","volume":"12","author":"Waldherr","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2025.111187_bib9","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1053\/snuc.2002.31769","article-title":"Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies","volume":"32","author":"Anthony","year":"2002","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.ejso.2025.111187_bib10","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00259-002-1050-8","article-title":"Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate","volume":"30","author":"Kwekkeboom","year":"2003","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.ejso.2025.111187_bib11","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1200\/JCO.2009.22.8585","article-title":"90 Y-Edotreotide for metastatic carcinoid refractory to octreotide","volume":"28","author":"Bushnell","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2025.111187_bib12","doi-asserted-by":"crossref","first-page":"501","DOI":"10.7150\/thno.13702","article-title":"[177 Lu-DOTA]0 -D-Phe1 -Tyr3 -Octreotide (177 Lu-DOTATOC) for peptide receptor radiotherapy in patients with advanced neuroendocrine tumours: a Phase-II study","volume":"6","author":"Baum","year":"2016","journal-title":"Theranostics"},{"key":"10.1016\/j.ejso.2025.111187_bib13","series-title":"Lutathera prescribing information","year":"2018"},{"key":"10.1016\/j.ejso.2025.111187_bib14","series-title":"Lutathera: summary of product characteristics","year":"2018"},{"key":"10.1016\/j.ejso.2025.111187_bib15","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of177 Lu-Dotatate for Midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejso.2025.111187_bib16","series-title":"SomaKit TOC: summary of product characteristics","year":"2017"},{"key":"10.1016\/j.ejso.2025.111187_bib17","series-title":"NETSPOT prescribing information","year":"2016"},{"key":"10.1016\/j.ejso.2025.111187_bib18","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s00259-012-2330-6","article-title":"The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours","volume":"40","author":"Zaknun","year":"2013","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.ejso.2025.111187_bib19","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1159\/000516015","article-title":"The state of peptide receptor radionuclide therapy and its sequencing among current therapeutic options for gastroenteropancreatic neuroendocrine tumors","volume":"111","author":"Raymond","year":"2021","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.ejso.2025.111187_bib20","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13423","article-title":"European Neuroendocrine Tumor Society (ENETS) 2024 guidance paper for the management of well\u2010differentiated small intestine neuroendocrine tumours","volume":"36","author":"Lamarca","year":"2024","journal-title":"J Neuroendocrinol"},{"key":"10.1016\/j.ejso.2025.111187_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2024.108544","article-title":"Surgical management of pancreatic neuroendocrine tumors \u2013 an EYSAC and E-AHPBA international survey of current practice","volume":"50","author":"Brandl","year":"2024","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejso.2025.111187_bib22","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.ejso.2021.10.003","article-title":"The ESSO core curriculum committee update on surgical oncology","volume":"47","author":"Van Der Hage","year":"2021","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejso.2025.111187_bib23","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.surg.2017.11.007","article-title":"Peptide receptor radionuclide therapy as neoadjuvant therapy for resectable or potentially resectable pancreatic neuroendocrine neoplasms","volume":"163","author":"Partelli","year":"2018","journal-title":"Surgery"},{"key":"10.1016\/j.ejso.2025.111187_bib24","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1007\/s00259-011-1835-8","article-title":"Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs)","volume":"38","author":"Sowa-Staszczak","year":"2011","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.ejso.2025.111187_bib25","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.2217\/fon.14.139","article-title":"Pet tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature","volume":"10","author":"Johnbeck","year":"2014","journal-title":"Future Oncol"},{"key":"10.1016\/j.ejso.2025.111187_bib26","doi-asserted-by":"crossref","first-page":"66","DOI":"10.2967\/jnumed.117.202275","article-title":"Appropriate use criteria for somatostatin receptor PET imaging in neuroendocrine tumors","volume":"59","author":"Hope","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ejso.2025.111187_bib27","doi-asserted-by":"crossref","DOI":"10.2967\/jnumed.120.257808","article-title":"Updates to the appropriate-use criteria for somatostatin receptor PET","volume":"61","author":"Hope","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ejso.2025.111187_bib28","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1159\/000471879","article-title":"ENETS Consensus guidelines for the standards of care in neuroendocrine tumors: radiological, nuclear medicine and hybrid imaging","volume":"105","author":"Sundin","year":"2017","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.ejso.2025.111187_bib29","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1007\/s00259-017-3670-z","article-title":"68Ga-PSMA PET\/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0","volume":"44","author":"Fendler","year":"2017","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.ejso.2025.111187_bib30","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s00259-019-04583-2","article-title":"The 68Ga\/177Lu-theragnostic concept in PSMA-targeting of metastatic castration\u2013resistant prostate cancer: impact of post-therapeutic whole-body scintigraphy in the follow-up","volume":"47","author":"Maffey-Steffan","year":"2020","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.ejso.2025.111187_bib31","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1007\/s00259-023-06255-8","article-title":"Joint EANM\/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)","volume":"50","author":"Kratochwil","year":"2023","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.ejso.2025.111187_bib32","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.5009","article-title":"Lutetium-177-PSMA-617 in oligo-metastatic hormone sensitive prostate cancer (BULLSEYE trial)","volume":"43","author":"Priv\u00e9","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2025.111187_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fddev.2024.1339936","article-title":"Future theranostic strategies: emerging ovarian cancer biomarkers to bridge the gap between diagnosis and treatment","volume":"4","author":"Rajapaksha","year":"2024","journal-title":"Front Drug Deliv"},{"key":"10.1016\/j.ejso.2025.111187_bib34","doi-asserted-by":"crossref","first-page":"204","DOI":"10.2967\/jnumed.122.264860","article-title":"SNMMI Procedure Standard\/EANM Practice guideline for SSTR PET: imaging neuroendocrine tumors","volume":"64","author":"Hope","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ejso.2025.111187_bib35","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1097\/RLU.0000000000002276","article-title":"68Ga PET imaging in patients with neuroendocrine tumors: a systematic review and meta-analysis","volume":"43","author":"Singh","year":"2018","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.ejso.2025.111187_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00006231-200601000-00001","article-title":"Radio-guided surgery of differentiated thyroid cancer using 131I or 99mTc-Sestamibi","volume":"27","author":"Rubello","year":"2006","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.ejso.2025.111187_bib37","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/RLU.0b013e3182291de8","article-title":"Radioguided surgery in neuroendocrine tumors using Ga-68-Labeled somatostatin analogs: a pilot study","volume":"37","author":"Kaemmerer","year":"2012","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.ejso.2025.111187_bib38","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1245\/s10434-024-15277-x","article-title":"Radio-guided surgery with a new-generation \u03b2-Probe for radiolabeled somatostatin analog, in patients with small intestinal neuroendocrine tumors","volume":"31","author":"Bertani","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2025.111187_bib39","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-34626-x","article-title":"Radioguided surgery with \u03b2 radiation: a novel application with Ga68","volume":"8","author":"Collamati","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejso.2025.111187_bib40","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.euo.2022.12.001","article-title":"Prostate-specific membrane antigen\u2013radioguided surgery facilitates pelvic lymph node dissection during radical prostatectomy for the treatment of locally advanced prostate cancer with regional lymph node metastases","volume":"6","author":"Lunger","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.ejso.2025.111187_bib41","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.euf.2025.05.003","article-title":"Radioguided surgery for prostate cancer","volume":"11","author":"Quarta","year":"2025","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.ejso.2025.111187_bib42","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2967\/jnumed.123.266495","article-title":"Prostate-specific membrane antigen\u2013targeted radioguided pelvic lymph node dissection in newly diagnosed prostate cancer patients with a suspicion of locoregional lymph node metastases: the DETECT trial","volume":"65","author":"Schilham","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ejso.2025.111187_bib43","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13425","article-title":"Role of neoadjuvant peptide receptor radionuclide therapy in unresectable and metastatic gastro\u2010entero\u2010pancreatic neuroendocrine neoplasms: a scoping review","volume":"37","author":"Kashyap","year":"2025","journal-title":"J Neuroendocrinol"},{"key":"10.1016\/j.ejso.2025.111187_bib44","doi-asserted-by":"crossref","DOI":"10.1093\/bjs\/znae178","article-title":"Neoadjuvant 177Lu-DOTATATE for non-functioning pancreatic neuroendocrine tumours (NEOLUPANET): Multicentre phase II study","volume":"111","author":"Partelli","year":"2024","journal-title":"Br J Surg"},{"key":"10.1016\/j.ejso.2025.111187_bib45","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.5_suppl.TPS431","article-title":"A phase I\/II study of neoadjuvant, intra-arterial administration of (177Lu)lutetium vipivotide tetraxetan in subjects with high-risk, localised or locally advanced prostate cancer (LUPUS)","volume":"43","author":"Kesch","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2025.111187_bib46","doi-asserted-by":"crossref","first-page":"znae317","DOI":"10.1093\/bjs\/znae317","article-title":"Care of neuroendocrine tumours: the collaborative of sUrgical teams for NeuroEndocrine Tumors (CUTNETs)","volume":"112","author":"Hallet","year":"2025","journal-title":"Br J Surg"},{"key":"10.1016\/j.ejso.2025.111187_bib47","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S2468-1253(24)00406-0","article-title":"Bridging gaps in surgical care for neuroendocrine tumours: CUTNETs begins","volume":"10","author":"Hallet","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.ejso.2025.111187_bib48","series-title":"Efficacy and safety of [177Lu]Lu-edotreotide vs everolimus in patients with grade 1 or grade 2 gastroenteropancreatic neuroendocrine tumours: COMPETE phase 3 trial","author":"Capdevila","year":"2025"},{"key":"10.1016\/j.ejso.2025.111187_bib49","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","volume":"403","author":"Singh","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ejso.2025.111187_bib50","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.4_suppl.TPS514","article-title":"Pivotal phase III COMPOSE trial will compare177 Lu-edotreotide with best standard of care for well-differentiated aggressive grade 2 and grade 3 gastroenteropancreatic neuroendocrine tumors","volume":"40","author":"Halfdanarson","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2025.111187_bib51","doi-asserted-by":"crossref","first-page":"16932","DOI":"10.18632\/oncotarget.24524","article-title":"Results and adverse events of personalized peptide receptor radionuclide therapy with 90Yttrium and 177Lutetium in 1048 patients with neuroendocrine neoplasms","volume":"9","author":"Baum","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejso.2025.111187_bib52","doi-asserted-by":"crossref","DOI":"10.1530\/endoabs.98.C32","article-title":"Myelodysplasia and leukemia instances after PRRT: experience from a tertiary institution","author":"Trikalinos","year":"2023","journal-title":"Endocr Abstr"},{"key":"10.1016\/j.ejso.2025.111187_bib53","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1055\/s-0043-1764308","article-title":"Screening for clonal hematopoiesis for mitigating the risk of hematopoietic neoplasms after PRRT","volume":"22","author":"Chandra","year":"2023","journal-title":"World J Nucl Med"},{"key":"10.1016\/j.ejso.2025.111187_bib54","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2967\/jnumed.120.242875","article-title":"Risk of bowel obstruction in patients with mesenteric or peritoneal disease receiving peptide receptor radionuclide therapy","volume":"62","author":"Strosberg","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ejso.2025.111187_bib55","doi-asserted-by":"crossref","DOI":"10.2967\/jnumed.121.262048","article-title":"Bowel obstruction as a complication of peptide receptor radionuclide therapy","volume":"62","author":"Wee","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ejso.2025.111187_bib56","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1159\/000503144","article-title":"Peritoneal carcinomatosis in gastro-entero-pancreatic neuroendocrine neoplasms: clinical impact and effectiveness of the available therapeutic options","volume":"110","author":"Merola","year":"2020","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.ejso.2025.111187_bib57","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/rpd\/ncu338","article-title":"Radiation exposure to caregivers from patients undergoing common radionuclide therapies: a review","volume":"167","author":"Stefanoyiannis","year":"2015","journal-title":"Radiat Protect Dosim"},{"key":"10.1016\/j.ejso.2025.111187_bib59","article-title":"SNMMI Mo99 shortage press release","year":"2024","journal-title":"SNMMIOrg"},{"key":"10.1016\/j.ejso.2025.111187_bib60","year":"2024"},{"key":"10.1016\/j.ejso.2025.111187_bib61","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1007\/s00259-021-05392-2","article-title":"Challenges and future options for the production of lutetium-177","volume":"48","author":"Vogel","year":"2021","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.ejso.2025.111187_bib63","series-title":"BfArM. 146-lutetiumtherapie-und-chelator","year":"2025"},{"key":"10.1016\/j.ejso.2025.111187_bib64","series-title":"Nutzenbewertung 177-Lu-PSMA","year":"2025"},{"key":"10.1016\/j.ejso.2025.111187_bib65","series-title":"Global challenges in the provision of Theranostic services the international atomic energy agency (IAEA) perspective","author":"Brink","year":"2025"},{"key":"10.1016\/j.ejso.2025.111187_bib66","doi-asserted-by":"crossref","DOI":"10.1007\/s40336-025-00695-y","article-title":"Advancing access to radioligand therapies for neuroendocrine tumours: the role of patient organizations","author":"Dureja","year":"2025","journal-title":"Clin Transl Imaging"},{"key":"10.1016\/j.ejso.2025.111187_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102141","article-title":"Peptide receptor radiotherapy re-treatment in patients with progressive neuroendocrine tumors: a systematic review and meta-analysis","volume":"93","author":"Strosberg","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejso.2025.111187_bib68","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41698-025-00938-1","article-title":"Emerging innovations in theranostics for pancreatic neuroendocrine tumors","volume":"9","author":"Karimi","year":"2025","journal-title":"npj Precis Oncol"},{"key":"10.1016\/j.ejso.2025.111187_bib69","doi-asserted-by":"crossref","DOI":"10.1007\/s40336-025-00692-1","article-title":"Alpha therapies: where and when is the future in neuroendocrine tumours?","author":"Vorster","year":"2025","journal-title":"Clin Transl Imaging"},{"key":"10.1016\/j.ejso.2025.111187_bib70","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.nucmedbio.2011.02.007","article-title":"The low-energy \u03b2\u2212 and electron emitter 161Tb as an alternative to 177Lu for targeted radionuclide therapy","volume":"38","author":"Lehenberger","year":"2011","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.ejso.2025.111187_bib71","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.3390\/molecules25174012","article-title":"Overview of radiolabeled somatostatin analogs for cancer imaging and therapy","volume":"25","author":"Eychenne","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.ejso.2025.111187_bib72","doi-asserted-by":"crossref","first-page":"682","DOI":"10.2967\/jnumed.123.265406","article-title":"The emergence of somatostatin antagonist\u2013based theranostics: paving the road toward another success?","volume":"64","author":"Imperiale","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ejso.2025.111187_bib73","doi-asserted-by":"crossref","first-page":"61S","DOI":"10.2967\/jnumed.116.186783","article-title":"Somatostatin receptor antagonists for imaging and therapy","volume":"58","author":"Fani","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ejso.2025.111187_bib74","article-title":"Long-term adverse events and survival of patients with neuroendocrine neoplasms (NEN) receiving peptide receptor radioligand therapy (PRRT) using 225Ac- and 225Ac-\/177Lu-labeled (TANDEM) antagonist DOTA-LM3: a retrospective analysis","volume":"65","author":"Perrone","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ejso.2025.111187_bib75","doi-asserted-by":"crossref","first-page":"940","DOI":"10.7150\/thno.91268","article-title":"Peptide receptor radionuclide therapy combinations for neuroendocrine tumours in ongoing clinical trials: status 2023","volume":"14","author":"Di Santo","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.ejso.2025.111187_bib79","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13046-021-01917-7","article-title":"Patient-derived organoids and high grade serous ovarian cancer: from disease modeling to personalized medicine","volume":"40","author":"Nero","year":"2021","journal-title":"J Exp Clin Cancer Res"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798325016154?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798325016154?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T13:25:24Z","timestamp":1768397124000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798325016154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":74,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0748798325016154"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2025.111187","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Theranostics in surgical oncology","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2025.111187","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"111187"}}